Skip to Content
Merck
  • Proteomics of Melanoma Response to Immunotherapy Reveals Mitochondrial Dependence.

Proteomics of Melanoma Response to Immunotherapy Reveals Mitochondrial Dependence.

Cell (2019-09-10)
Michal Harel, Rona Ortenberg, Siva Karthik Varanasi, Kailash Chandra Mangalhara, Mariya Mardamshina, Ettai Markovits, Erez N Baruch, Victoria Tripple, May Arama-Chayoth, Eyal Greenberg, Anjana Shenoy, Ruveyda Ayasun, Naama Knafo, Shihao Xu, Liat Anafi, Gali Yanovich-Arad, Georgina D Barnabas, Shira Ashkenazi, Michal J Besser, Jacob Schachter, Marcus Bosenberg, Gerald S Shadel, Iris Barshack, Susan M Kaech, Gal Markel, Tamar Geiger
ABSTRACT

Immunotherapy has revolutionized cancer treatment, yet most patients do not respond. Here, we investigated mechanisms of response by profiling the proteome of clinical samples from advanced stage melanoma patients undergoing either tumor infiltrating lymphocyte (TIL)-based or anti- programmed death 1 (PD1) immunotherapy. Using high-resolution mass spectrometry, we quantified over 10,300 proteins in total and ∼4,500 proteins across most samples in each dataset. Statistical analyses revealed higher oxidative phosphorylation and lipid metabolism in responders than in non-responders in both treatments. To elucidate the effects of the metabolic state on the immune response, we examined melanoma cells upon metabolic perturbations or CRISPR-Cas9 knockouts. These experiments indicated lipid metabolism as a regulatory mechanism that increases melanoma immunogenicity by elevating antigen presentation, thereby increasing sensitivity to T cell mediated killing both in vitro and in vivo. Altogether, our proteomic analyses revealed association between the melanoma metabolic state and the response to immunotherapy, which can be the basis for future improvement of therapeutic response.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-ACAT1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Sigma-Aldrich
Collagenase from Clostridium histolyticum, suitable for release of physiologically active rat hepatocytes, Type IV, 0.5-5.0 FALGPA units/mg solid, ≥125 CDU/mg solid
Sigma-Aldrich
Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone, ≥98% (TLC), powder
Sigma-Aldrich
Salicylic acid, puriss. p.a., ≥99.0% (T)
Supelco
Empore SPE Disks, Cation Exchange, diam. 47 mm, pk of 20
Sigma-Aldrich
Anti-FABP7 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Sigma-Aldrich
(+)-Etomoxir sodium salt hydrate, ≥98% (HPLC), powder
Sigma-Aldrich
Sodium dichloroacetate, 98%
Sigma-Aldrich
Rotenone, ≥95%
Sigma-Aldrich
Antimycin A from Streptomyces sp.
Supelco
Empore SPE Disks, matrix active group C18, diam. 47 mm, pk of 20
Sigma-Aldrich
Anti-ACOT1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution